Trials / Unknown
UnknownNCT04897386
Monitoring the Efficacy of Duvalizumab Combined With Neoadjuvant Chemotherapy for Ib-IIIb NSCLC by Sequencing of Immune Receptor Repertoire: a Prospective, One Arm Clinical Study
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To observe and evaluate the efficacy and safety of Duvalizumab Combined With Neoadjuvant Chemotherapy for Ib-IIIb NSCLC and the relevance with Immune Receptor Repertoire
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Duvalizumab | Pemetrexed 850 mg, IV, Day1; Platinum 50mg / m2, IV, day1, once every 3 weeks, duvalizumab treatment, 1500mg, day1, a total of 4 cycles, once every 3 weeks. 4 cycles in total |
Timeline
- Start date
- 2021-06-01
- Primary completion
- 2024-06-01
- Completion
- 2024-12-01
- First posted
- 2021-05-21
- Last updated
- 2021-05-21
Source: ClinicalTrials.gov record NCT04897386. Inclusion in this directory is not an endorsement.